Abstract. 3,5,3'-triiodothyroacetic acid is an effective inhibitor of TSH secretion in central hyperthyroidism. Serum 3,5,3'-triiodothyroacetic acid was measured with an RIA preceded by immunoprecipitation. An anti \x=req-\ 3,5,3'-triiodothyroacetic acid antibody was obtained in rabbits, using 3,5,3'-triiodothyroacetic acid coupled to hemocyanin and diazotized benzidine as antigen (crossreactivity with T4, T3, tetraiodothyroacetic acid was 0.2, 1.1, and 5%, respectively). Endogenous 3,5,3'-triiodothyroacetic acid levels could not be detected in 14 euthyroid, 10 hypothyroid and 10 hyperthyroid sera (detection limit 0.055 nmol/l). Kinetic studies were performed in 6 healthy male subjects who received an oral and an iv dose of 1050 \g=m\g of 3,5,3'-triiodothyroacetic acid. The serum measurements were analysed according to a non-compartmental method. The half-life of 3,5,3'-triiodothyroacetic acid was 6 h 22 min \ m=+-\ 29 min, the volume of distribution was 114 \ m=+-\ 9 1/70 kg, and the plasma clearance rate was 298 \m=+-\14 1 \m=.\ (70 kg)\m=-\1 \m=.\ day\m=-\1. Highest 3,5,3'-triiodothyroacetic acid levels were measured after 40 min (for T3 2\p=n-\3h) and its absorption was 67\m=+-\6%. 
dothyroacetic acid levels were measured after 40 min (for T3 2\p=n-\3h) and its absorption was 67\m=+-\6%.The nadir of the mean TSH levels was 0.72 \ m=+-\0.09 mU/l 6 h after 3,5,3' \x=req-\ triiodothyroacetic acid administration. However, the time course of serum TSH response did not differ from that obtained after administration of 37.5 \g=m\gT3. The dose-response effect for TSH was studied using oral doses of 350, 700, 1400 and 2800 \ g=m\ g3,5,3'-triiodothyroacetic acid. TSH was measured 9 h after 3,5,3'-triiodothyroacetic acid administration at 17.00 h, and compared with control serum TSH levels obtained at 08.00 h (1.53 \ m=+-\ 0.11) and at 17.00 h the day before the test (1.87 \ m=+-\0.11). They were 1.05 \ m=+-\0. 15 (N = 9, mean \ m=+-\ sem), 0.83 \ m=+- \0.08 (N = 24), 0.66 \ m=+-\ 0.06 (N = 24), and 0.43 \ m=+-\ 0.02 mU/l (N = 6),
respectively. In conclusion, TSH inhibition by 3,5,3'-triiodothyroacetic acid is similar to T3, with a potency ratio of 1 to 18.
The acetic acid analogues were described as occur¬ ring in vivo in 1952, when Gross & Pitt-Rivers dis¬ covered the appearance of labelled 3,5,3'-triiodothyroacetic acid (TRIAC) after T3 administration to rats (1) . The role of this pathway is not clearly es¬ tablished even though studies in man demon¬ strated that a large fraction of Cl4-labelled T4 was eliminated in the urine as the acetic acid analogue of thyronine (2) . Serum 
Kinetic studies
The kinetic data are shown in Fig. 2 (Fig. 5), the nadir of the mean levels was identical (0.72 ± 0.14 mU/1) 8 h after administration. At 24 h after TRIAC and 36 h after T3, serum TSH levels were not different from the control levels. By analysis of variance for repeated measurements, there was no difference over time between the effect on TSH of TRIAC or T3 (p = 0.57). Assuming a 100% absorp¬ tion of T3, the molar potency ratio for T3 to TRIAC is 18 to 1.
The dose-dependency of TSH inhibition by TRIAC was evaluated 9 h after administration, at 17.00 h (Fig. 6) 6 h 22 min ± 29 min, whereas for T3 it is reported to be 23 h (7, 8) . The plasma clearance rate was 298 1/day which is slightly higher than the 222 1/day previously re¬ ported (10) . On the basis of our serum concentra¬ tions and plasma clearance rate, one can conclude that in healthy euthyroid, hyperthyroid, hypothyroid or cholestatic subjects, serum production rate of TRIAC is minimal.
In cell cultures, the nuclear thyroid receptor has been shown to have an equal or greater affinity for TRIAC than for T3 and recently it has been shown that the product of the r-Erb Aß-2 gene a T3-receptor protein, has a greater affinity for TRIAC than for T3. This gene is expressed at high levels in the rat anterior pituitary (12) .
In central hyperthyroidism, TRIAC has been re¬ ported to be an effective inhibitor of serum TSH with little peripheral action (13) (14) (15) 
